METITsILLINREZISTENTNYE ZOLOTISTYE STAFILOKOKKI: PROBLEMA RASPROSTRANENIYa V MIRE I ROSSII


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) are the leading causative agents of nosocomial infections; they were first described in 1961 in England, and now are spreading worldwide. The most important feature of MRSA is resistance to most в-lactam antibiotics, as well as the high incidence of associated resistance to antibiotics of other groups. Of particular concern is the emergence and spread of MRSA with reduced susceptibility to vancomycin and isolates resistant to daptomycin, linezolid, tigecycline and ceftaroline. Isolates with reduced susceptibility to these drugs are already registered in the Russian Federation. This review summarizes recent data on the expantion, antibiotic resistance, and molecular epidemiology of MRSA. The modern pharmacotherapies for the treatment and prospects of therapy of MRSA-infections are discussed.

Full Text

Restricted Access

About the authors

V. V Gostev

S. V Sidorenko

References

  1. Jevons M. Celbenin - resistant Staphylococci. Br. Med. J. 1961;5219( 1): 124-25.
  2. CDC MRSA Statistics. http://www.cdc.gov/ mrsa/statistics/index.html
  3. David M.Z., Daum R.S. Community-associated methicillin-resistant Staphylococcus aureus: epidemiol,gy and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev. 2010;23(3):616-87.
  4. Hiramatsu K, Hanaki H., Ino T., Yabuta K., Oguri T, Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 1997;40(1):135-36.
  5. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin. Infect. Dis. 2006;42(1):S25-34.
  6. Schneider-Lindner V., Delaney J.A., Dial S., Dascal A., Suissa S. Antimicrobial drugs and community-acquired methicillin-resistant Staphylococcus aureus, United Kingdom. Emerg. Infect. Dis. 2007;13(7):994-1000.
  7. Merchant S, Gast C., Nathwani D., Lee M., Quintana A., Ketter N., Friedland I., Ingham M. Hospital resource utilization with doripe- nem versus imipenem in the treatment of ventilator-associated pneumonia. Clin. Ther. 2008;30(4):71 7-33.
  8. Enright, M.C., DayN.P., Davies C.E., PeacockS.J., Spratt B.G. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J. Clin. Microbiol. 2000;38(3): 1008-15.
  9. EARS-Net database. http://ecdc.europa.eu/ en/activities/surveillance/EARS-Net/database/ Pages/database.aspx.
  10. Schaumburg, F., Alabi A.S., Peters G., Becker K. New epidemiology of Staphylococcus aureus infection in Africa. Clin. Microbiol. Infect. 2014; 20(7):589-96.
  11. Chen C.J., Huang Y.C. New epidemiology of Staphylococcus aureus infection in Asia. Clin. Microbiol. Infect. 2014;20(7):605-23.
  12. Rodriguez-Noriega E., Seas C., Guzman- Blanco M., Mejia C., Alvarez C., Bavestrello L., Zurita J., Labarca J., Luna C.M., Salles M.J., Gotuzzo E. Evolution of methicillin-resistant Staphylococcus aureus clones in Latin America. Int. J. Infect. Dis. 2010;14(7):e560-66.
  13. Williamson D.A., Coombs G.W., Nimmo G.R. Staphylococcus aureus 'Down Under': contemporary epidemiology of S. aureus in Australia, New Zealand, and the South West Pacific. Clin. Microbiol. Infect. 2014;20(7):597-604.
  14. Smith, T.C., Pearson N. The emergence of Staphylococcus aureus ST398. Vector Borne Zoonotic. Dis. 2011;(4):327-39.
  15. Kock R., Becker K., Cookson B., van Gemert- Pijnen J.E., Harbarth S., Kluytmans J., Mielke M., Peters G., Skov R.L., Struelens M.J., Tacconelli E., Navarro Torne A., Witte W., Friedrich A.W. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill. 2010; 15(41): 19688.
  16. Joana S., Pedro P., Elsa G., Filomena M. Is vancomycin MIC creep a worldwide phenomenon? Assessment of S. aureus vancomycin MIC in a tertiary university hospital. BMC Res. Notes. 2013;6:65.
  17. Steinkraus G., White R., Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin- susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 2007;60(4):788-94.
  18. Edwards B., Milne K., Lawes T., Cook I., Robb A., Gould I.M. Is vancomycin MIC «creep» method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. J. Clin. Microbiol. 2012; 50(2):318-25.
  19. Ho P.L., Lo P.Y., Chow K.H., Lau E.H., Lai E.L., Cheng V.C., Kao R.Y. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. J. Infect. 2010;60(2):140-45.
  20. de Sanctis, J.T., Swami A., Sawarynski K., Gerasymchuk L., Powell K., Robinson-Dunn B., Carpenter C.F., Sims M.D. Is there a clinical association of vancomycin MIC creep, agr group II locus, and treatment failure in MRSA bacteremia? Diagn. Mol. Pathol.2011;20(3):184-88.
  21. van HalS.J., Lodise T.P., Paterson D.L. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin. Infect. Dis. 2012;54(6):755-71.
  22. Wi Y.M., Kim J.M., Joo E.J., Ha Y.E., Kang C.I., Ko K.S., Chung D.R., Song J.H., Peck K.R. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia. Int. J. Antimicrob. Agents. 2012;40(2):108-13.
  23. Perichon B., Courvalin P. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2009;53( 11 ):4580-87.
  24. Aligholi, M., Emaneini M., Jabalameli F., Shahsavan S., Dabiri H., Sedaght H. Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini Hospital in Tehran. Med. Princ. Pract. 2008;17(5):432-34.
  25. Moravvej, Z., Estaji F., Askari E., Solhjou K., Naderi Nasab M., Saadat S. Update on the global number of vancomycin-resistant Staphylococcus aureus (VRSA) strains. Int. J. Antimicrob. Agents. 2013;42(4):370-71.
  26. Saha B., Singh A.K., Ghosh A., Bal M. Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J. Med. Microbiol. 2008;57(Pt 1):72-9.
  27. Baranovich T, Potapov V., Yamamoto T. The first isolation of Panton-Valentine leukocidin (PVL) positive community-acquired methicillin- resistant Staphylococcus aureus (CA-MRSA) in Russia. Euro Surveill. 2007;12(3):E0703154.
  28. Romanov, A.V., Chernov E.A., Edelstein M.V. Molecular epidemiology of nosocomial staphylococcus aureus in hospitals in different regions of Russia. Mol. Med. 2013;4:55-64.
  29. Romanov A.V., Dekhnich A.V., Edelstein M.V. Molecular Epidemiology of Staphylococcus aureus in Russian Pediatric Hospitals. CMAC. 2012;14(3):201-8.
  30. Dmitrenko O.A., Shaginian I.A., Prokhorov V.I., Matveev S.M., Gintsburg A.L. Molecular genetic typing of methicillin-resistant Staphylococcus aureus strains, isolated in hospitals of different regions of the Russia and Belarus. Zh. Mikrobiol. Epidemiol. Immunobiol. 2005;4:46-52.
  31. Сидоренко С.В., Резван С.П., Грудинина С.А., Кротова Л.А., Стерхова Г.В. Результаты многоцентрового исследования чувствительности стафилококков к антибиотикам в Москве и Санкт-Петербурге. Антибиотики и химиотерапия. 1998;7: 15-25.
  32. Дмитренко О.А. Молекулярно-генетические аспекты эпидемиологии внутрибольничных инфекций, вызванных представителями вида Staphylococcus aureus, устойчивыми к метициллину/оксациллину. Автореф. дис д.м.н. М., 2008. 43 c.
  33. Дехнич А.В., Гугуцидзе Е.Н., Ахметова Л.И., Афиногенов Г.Е., Воронина Л.Г., Кречико- ва О.И., Эйдельштейн И.А., Марусина Н.Е., Ильина В.Н., Гудкова Л.В., Здзитовецкий Д.Э., Мултых И.Г., Нарезкинсг А.Д. Эпидемиология антибиотикорезистентности нозокомиальных штаммов Staphylococcus aureus в России: результаты многоцентрового исследованияю. КМАХ. 2002;4(4):325-36.
  34. Сабирова Е.В., Гординская Н.А., Абрамова Н.В., Некаева Е.С. Антибиотикорезистентность нозокомиальных штаммов Staphylococcus spp., выделенных в ожоговом центре в 2002-2008 гг. КМАХ. 2010;12(1):77-81.
  35. Дехнич А.В., Козлов Р.С., Кречикова О.И., Рябкова Е.Л., Сухорукова М.В., Никулин А.А. Эпидемиология резистентности штаммов S. aureus, выделенных от пациентов в ОРИТ Российских стационаров: результаты многоцентрового исследования. КМАХ. 2008; 10(4):333-44.
  36. Науменко З.С., Гостев В.В., Богданова Н.А. Сравнительная оценка динамики антибиотикорезистетности бактерий, выделенных у больных с острым и хроническим гнойным процессом в ортопедотравматологическом стационаре. Гений ортопедии. 2010;3:141-45.
  37. Решедько Г.К., Авдеева Т.Г., Иванчик Н.В., Стунжас О.С. Антибиотикорезистентность штаммов S.aureus, выделенных у детей раннего возраста с инфекциями кожи и мягких тканей. КМАХ. 2009;11(4):356-61.
  38. Gostev V.V., Popenko L.N., Chernen'kaia T.V., Naumenko Z.S., Voroshilova T.M., Zakharova Iu.A., Khokhlova O.E., Kruglov A.N., Ershova M.G., Angelova S.N., Poletaeva E.D., Molchanova I.V., Sidorenko S.V. Estimation of MRSA susceptibility to oxacillin, cefoxi- tine, vancomycin and daptomycin. Antibiot. Khimioter. 2013;58(9-10):13-20.
  39. Wootton M., Howe R.A., Hillman R., Walsh T.R., Bennett P.M., MacGowan A.P. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 2001; 47(4):399-403.
  40. Liu C., Bayer A., Cosgrove S.E., Daum R.S., Fridkin S.K., Gorwitz R.J., Kaplan S.L., Karch- mer A.W., Levine D.P., Murray B.E., J Rybak M., Talan D.A., Chambers H.F.; Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 2011; 52(3): e18-55.
  41. Gould F.K. Brindle R., Chadwick P.R., Fraise A.P., Hill S., Nathwani D., Ridgway G.L., Spry M.J., Warren R.E.; MRSA Working Party of the British Society for Antimicrobial Chemotherapy. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J. Antimicrob. Chemother. 2009;63(5):849-61.
  42. Rybak M.J., Lomaestro B.M., Rotschafer J.C., Moellering R.C., Craig W.A., Billeter M., Dalovisio J.R., Levine D.P. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. 2009;49(3):325-27.
  43. Friedland H.D., O'Neal T., Biek D., Eckburg P.B., Rank D.R., Llorens L., Smith A., Witherell G.W., Laudano J.B., Thye D. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob. Agents Chemother. 2012;56(5): 2231-36.
  44. Yang L.P., Keam S.J. Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs. 2008;68(6):855-73.
  45. Steenbergen J.N., Alder J., Thorne G.M., Tally F.P. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 2005; 55(3):283-88.
  46. Stein G.E., Craig W.A. Tigecycline: a critical analysis. Clin. Infect. Dis. 2006;43(4):518-24.
  47. Kanafani Z.A., Corey G.R. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin. Investig. Drugs. 2012;21(4): 515-22.
  48. Rodriguez-Avial I., Culebras E., Betriu C., Morales G., Pena I., Picazo J.J. In vitro activity of tedizolid (TR-700) against linezolid-resis- tant staphylococci. J. Antimicrob. Chemother. 2012;67(1):167-69.
  49. Bailey J., Summers K.M. Dalbavancin: a new lipoglycopeptide antibiotic. Am. J. Health. Syst. Pharm. 2008;65(7): 599-610.
  50. Polyzos, K.A., Mavros M.N., Vardakas K.Z., Makris M.C., Rafailidis P.I., Falagas M.E. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. PLoS One. 2012;7(8): e41870.
  51. Zhanel, G.G., CalicD., SchweizerF., ZelenitskyS., Adam H., Lagace-Wiens P.R., Rubinstein E., Gin A.S., Hoban D.J., Karlowsky J.A. New lipo- glycopeptides: a comparative review of dal- bavancin, oritavancin and telavancin. Drugs. 2010;70(7):859-86.
  52. Lamb H.M., Figgitt D.P., Faulds D. Quinupristin/ dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999;58(6): 1061-97.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies